212 results about "Trophoblast" patented technology

The invention discloses a step-by-step targeting placenta trophoblast micro-nano robot as well as a preparation method and application thereof. The micro-nano robot comprises a yeast cell wall of a bag-shaped structure, bio-enzyme unevenly distributed on the surface of the yeast cell wall and targeted placenta trophoblast drug-loaded nanoparticles located in the yeast cell wall. The surfaces of the targeted placenta trophoblast drug-loaded nanoparticles are connected with placenta-like chondroitin sulfate A binding polypeptides. Inflammation placenta tissue can be targeted through macrophages, the medicine is accurately delivered to placenta trophoblastic cells through the medicine-carrying nano-particles connected with the targeting peptide, step-by-step accurate targeting is achieved, the medicine does not penetrate through the placenta barrier to reach the body of a fetus, and high biological safety is achieved for pregnancy administration.

The invention belongs to the technical field of biomedicine, and particularly relates to a preparation method of human nourishing stem cells induced by human extended potential stem cells, which comprises the following specific steps: step 1, converting H9 human embryonic stem cells into adult extended potential stem cells on the basis of a feeder-layer-free system: (1) coating culture dishes with Matrigel, adding 1ml of Matrigel working solution into 35 dishes, and uniformly stirring; placing in an incubator at 37 DEG C overnight, and fully coating the dish bottom with the substrate for later use; according to the application, H9 human embryonic stem cells are converted into adult extended potential stem cells on the basis of a feeder-layer-free system; based on a human trophoblast stem cell culture system, feeder-layer-free human extended potential stem cells are differentiated into induced human trophoblast stem cells, and finally the induced human trophoblast stem cells are identified and induced to differentiate, so that interference of feeder-layer cells on the induced trophoblast stem cells is eliminated, and the induction efficiency of the induced trophoblast stem cells under the feeder-layer-free system is ensured.

The invention provides an embryo three-dimensional reconstruction method and device, electronic equipment and a storage medium, and relates to the technical field of embryo quality evaluation. Comprising the following steps: acquiring a multi-focal original plane image of a blastocyst to be reconstructed based on a time difference incubator; adopting a pre-trained image frame interpolation model to perform iterative frame interpolation processing on the multi-focal original plane image to generate a multi-focal extended plane image corresponding to each iteration; according to the multi-focus original plane image and the multi-focus extended plane image corresponding to each round of iteration, adopting an auxiliary circle marking algorithm to mark a blastocyst main body area in each focus original plane image and each focus extended plane image; respectively extracting mask images of a plurality of inner cell clusters and mask images of a plurality of trophoblast cells on the basis of marking results; and performing three-dimensional reconstruction according to the extracted mask images of the internal cell clusters and the mask images of the trophoblast cells to obtain curved surface models of the internal cell clusters and curved surface models of the trophoblast cells. The method improves the reconstruction precision.

The invention provides biopsy liquid and application thereof in pig blastocyst laser cutting, and belongs to the technical field of animal biology. The invention provides a biopsy solution and a preparation method thereof, the biopsy solution can be applied to pig blastocyst biopsy by laser cutting, the problem that at present, no adaptive biopsy solution exists for laser cutting of pig blastocyst is solved, and the invention further provides a method for laser cutting of pig blastocyst by using the biopsy solution. The problems of embryo cell injury, embryo development potential damage and the like possibly caused by laser cutting of the pig blastocyst in the prior art are solved. The biopsy liquid and the use method thereof can be efficiently and accurately applied to acquisition of pig blastocyst trophoblast cells, and are low in cost and good in repeatability.

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The invention relates to bovine trophoblast stem cells and application thereof.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of circ0005704 and related biological elements thereof in diagnosis and treatment of recurrent spontaneous abortion with unknown reasons. Researches find that differential expression and autophagy level of ULK1 in trophoblast cells of URSA patients are increased. High-throughput transcriptome sequencing is combined with bioinformatics analysis, and it is found that miR-26a-5p is down-regulated in URSA patients, is responsible for up-regulation of ULK1 and promotes autophagy of trophoblast cells, so that occurrence of URSA is increased. Through a high-throughput transcriptional set screening strategy and dual luciferase reporter gene analysis, it is found that circ0005704 enhances the expression of ULK1 through miR-26a-5p. In a word, the research of the invention shows that the circ0005704 / miR-26a-5p / ULK1 signal axis participates in the pathogenesis of URSA by adjusting the migration of the trophoblast cells, and a new target and scientific evidence are provided for the clinical treatment of URSA.

The invention belongs to the field of immunology, and particularly relates to amplification of NK cells, in particular to a method for amplifying NK cells by using NK92 cells as trophoblast cells, which specifically uses NK92 cells secreting IL-21, IL-15 and IL-18 as trophoblast cells and PBMC as seed cells to directionally amplify and activate natural killer cells, and comprises the following steps: transfecting an NK92 cell strain through lentivirus; the NK92 cell strain capable of stably expressing IL-21, IL-15 and IL-18 is obtained; then obtaining monoclonal cells of NK92 cells through flow sorting and limit dilution methods, finally culturing and amplifying, preparing NK92 trophoblasts through irradiation, and mixing the NK92 trophoblasts with PBMC (peripheral blood mononuclear cells) for culturing so as to prepare the NK cells. According to the method, the NK cells can be efficiently amplified and activated, and the activated NK cells can improve the immunity of the organism, so that tumor and virus infection is resisted. The invention has wide application in medicine.

The invention relates to a recurrent abortion early-warning method based on maternal and fetal immune interaction characteristics, which comprises the following steps: by taking decidua immune cells and trophoblasts as a unit, defining the regulation intensity of a key path of a path in an immune receptivity state; evaluating the coordination degree of signals among different cells by utilizing an information theory method; introducing a maternal and fetal immune receptivity steady-state index UISI; through continuous time sampling analysis, an immune signal offset track is identified; establishing an interactive imbalance index (IEI), and quantifying the imbalance intensity; designing a disturbance and response test; fitting the response trend of the IEI change to the disturbance into a system response curve IRC, and quantifying the recovery capability of the immune system; the IRC and individual clinical features are fused, and a dynamic risk thermodynamic relation is established; intervention window weight factors are constructed, wherein the intervention window weight factors comprise the fluctuation amplitude, the recovery period and the UISI critical value proximity; outputting a dynamic intervention suggestion map, and prompting a doctor to observe a period and a drug intervention starting point; the early warning capability is strong, and the limitation of traditional passive diagnosis is broken through.

The invention discloses a construction method of a trophoblast organ-like model, the trophoblast organ-like model and application thereof, and relates to the technical field of cell model.The construction method comprises the steps that placenta villus tissue is aseptically separated, gradient separation and purification are conducted to obtain extraembryonic early cells, the extraembryonic early cells are mixed with matrigel, and the trophoblast organ-like model is obtained; and carrying out 3D culture by using a culture medium containing early-stage and later-stage differentiation compositions to obtain the organ-like model with various trophoblast cell lineages. Based on the model, placenta toxicity research is carried out on pregnancy drugs, and the research specifically comprises the degree of 3D organoid form destruction after drug treatment, organoid activity and the expression condition of trophoblast marker genes. Compared with a traditional two-dimensional cell model, the placental toxicity detection method has the advantages that the placental toxicity of the medicine is detected by taking the trophoblast-like organ as the model, the accuracy is higher, the predictability is higher, and the influence of the medicine on human placental tissues is accurately reflected.

The invention discloses application of vitamin D3 in preparation of a product for improving trophoblast proliferation inhibition. The research proves that the vitamin D3 can obviously improve the proliferation inhibition of palmitic acid on human trophoblast cells; the vitamin D3 can reduce palmitic acid induced cell active oxygen level up-regulation; vitamin D3 can up-regulate expression of Nrf-2, HO-1 mRNA and protein in cells induced by palmitic acid. Vitamin D3 can improve palmitic acid induced human trophoblast cell proliferation inhibition by activating an Nrf2 / HO-1 pathway. The invention provides a new product for improving the proliferation inhibition of palmitic acid on human trophoblast cells, and has a good clinical application prospect.

The invention provides a trophoblast cell characteristic analysis method and electronic equipment, and relates to the technical field of embryo evaluation. The method comprises the following steps: carrying out space quadrant division on a target blastocyst three-dimensional model obtained by three-dimensional reconstruction to obtain a plurality of sub-quadrants; determining polar trophoblast cell information and wall trophoblast cell information according to the internal cell mass information in each sub-quadrant; determining multiple fusion feature data according to the trophoblast cell information, the polar trophoblast cell information and the wall trophoblast cell information in each sub-quadrant; and according to the fusion feature data and the basic feature data, carrying out embryo development result analysis to obtain estimated development result information of the target blastocyst. According to the scheme, the spatial structure features of the trophoblast cells are fully mined to obtain the fusion features, and the embryonic development result can be analyzed more deeply based on the fusion features, so that the accuracy of embryonic development result evaluation is improved, and clinical selection of embryos with higher development potential is assisted.

The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.

Provided are a promoter of a gene specifically expressed in fetal trophoblast cells and a gene specifically expressed in fetal nucleated red blood cell-specific expression gene, as well as a recombinant herpes simplex virus type I obtained by replacing the wild type promoter of the genomic ICP of the recombinant herpes simplex virus type I with the aforesaid promoter and preparation and use thereof. Also provided are a diagnostic kit for prenatal screening and use thereof, as well as a method for isolating fetal cells from a maternal blood sample in pregnancy.

The invention relates to a method for inducing mouse trophoblast stem cells in vitro. According to the method, mouse embryonic stem cells are used as starting cells, Sorcs3 gene knockout mouse embryonic stem cells are obtained through a gene editing technology, and in-vitro induced trophoblast stem cells (iTSCs) are efficiently and rapidly obtained by means of a flow cytometry sorting technology and in combination with specific antibody sorting. According to the invention, the Sorcs3 gene is knocked out from the embryonic stem cell, so that the capability of the embryonic stem cell to differentiate to the trophoblast lineage can be obviously enhanced; an important research platform is provided for deeply researching a lineage intertransformation mechanism of cell masses (ICM) and trophoblast (TE) in the blastocysts, and the method has important significance for researching lineage limitation of early embryonic development of mammals and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

The invention relates to a preparation method of human haploid trophoblast stem cells, which comprises the following steps: inoculating haploid embryonic stem cells (hAG-ESCs) into a culture medium of human trophoblast stem cells (TSC), domesticating, and when TSC sample clones account for more than 50% of the proportion of all cells in the induction process, carrying out flow sorting on ITGA6 positive cells, and inoculating into the TSC culture medium again for culturing to obtain the human haploid trophoblast stem cells. After the culture, haploid trophoblast stem cells (haiTSCs) are obtained; the prepared haiTSCs are haploids, and have TSC properties. The preparation method is rapid and efficient, and the haiTSCs can be used for simulating an in-vivo disease model and have the genetic screening advantage of haploids.

The invention provides a biological preparation for regulating placenta dysplasia, and belongs to the technical field of gynaecology and obstetrics. Core effective components of the biological preparation are lutjanus mixed polypeptide with the molecular weight ranging from 2 kDa to 10 kDa, and the lutjanus mixed polypeptide is prepared by combining lutjanus fish bones, fish scales and fish flesh according to the mass ratio of 5: 3: 2 through the steps of desalting treatment, ultrasonic-assisted degreasing, double-enzyme synergistic enzymolysis, double ultrafiltration purification and the like. Experimental results show that the lutjanus mixed polypeptide has a remarkable protection effect on a human trophoblast cell line HTR-8 / SVneo in a high-glucose environment, and can effectively promote cell proliferation and migration and reduce high-glucose-induced cell damage. Therefore, the biological preparation provides a novel effective intervention means for placenta dysplasia caused by gestational diabetes mellitus, and has a good application prospect.

Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.

The invention discloses a method for relieving vomitoxin induced porcine placental trophoblast cell injury by chlorogenic acid, which optimizes the conditions of CGA treatment of porcine placental trophoblast pTr cells, including treatment concentration and treatment time, and evaluation of DON relieving effect. Important experimental materials and technical methods are provided for further relieving cytotoxicity caused by mycotoxin by using the CGA.

The invention relates to a method for detecting trophoblast residues in an NK cell product and application of the method. The method comprises the following steps: extracting nucleic acid molecules of the NK cell product, and detecting whether trophoblast specific gene segments exist in the nucleic acid molecules or not. According to the method, the residual condition of the trophoblasts in the NK cell final product is detected by a molecular biological method, specifically, detection can be performed in a manner of amplifying specific genes of the trophoblasts through qPCR or amplifying STR loci of the NK cells through PCR, the method is simple, convenient and rapid, the accuracy rate is high, and the detection precision is improved by combining multiple methods, so that the accuracy of a detection result is ensured.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention relates to a preparation method of a placenta trophoblast-derived transporter and application of the placenta trophoblast-derived transporter in a medicine for treating spontaneous abortion, which comprises the following steps of: taking out a placenta of a suckling mouse, cutting the placenta into fine tissue blocks, resuspending by using digestive juice, digesting in a water bath kettle at 37 DEG C for 20 minutes, and then stopping digestion by using 1640 culture containing high-temperature heat-inactivated fetal calf serum; diluting and neutralizing collagenase digestive juice according to 5 times of volume; and centrifuging the collagenase digestive juice for multiple times to obtain a precipitate, namely the exosome. And carrying out density gradient centrifugation on the coarse migration body by using Optiprep as a density medium, washing, precipitating and centrifuging by using PBS on an ultra-high-speed centrifuge by using a horizontal rotor to obtain the placental trophoblast source migration body. The invention finds that the generation of the placental trophoblast cell source migration body is related to the physiological process of pregnancy for the first time, and the placental trophoblast cell source migration body can enter the circulatory system and reach the placenta through in-vitro supplementation.

To provide an implantation rate improving agent that is easily produced, a pharmaceutical composition containing the implantation rate improving agent, and a method for producing the implantation rate improving agent.SOLUTION: Provided is an implantation rate improving agent comprising a culture supernatant of trophoblastic stem cells. Also provided is a pharmaceutical composition for treating or preventing implantation failure, which comprises the implantation rate improving agent. Also provided is a method for producing an implantation rate improving agent, comprising the steps of (i) culturing trophoblastic stem cells, and (ii) obtaining a culture supernatant from the culture obtained by the culturing.SELECTED DRAWING: None

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The invention relates to a method for detecting early embryo death of cattle and sheep, which is characterized by comprising the following steps of: 1) determining the detection time of early embryo death: when oestrus behavior characteristics of cows and ewes are observed by a pedometer or naked eyes, determining the time as the detection time; 2) detecting early embryo death: taking 5-10ml of cow and ewe blood, standing for 1-2 hours in a shade place, separating serum, respectively inserting bovine trophoderm protein-1 detection test paper and sheep trophoderm protein-1 detection test paper into the cow and ewe serum for 5-10 minutes, observing the detection test paper 15-18 minutes after the detection test paper is taken out, and when the detection test paper develops color, detecting the early embryo death; the cows or ewes are successfully fertilized and form early embryos, but still have estrus behavior characteristics, and the embryos are proved to be dead. Whether embryos die or not can be detected in time, the problems that the feeding cost is increased in the non-pregnant period, the number of fertilization opportunities caused by blind mating is small, and wombs of cattle and sheep are injured are solved, and by reasonably waiting for mating, the breeding efficiency is greatly improved, the yield of milk and goat milk is increased, and the income of a feeding farm is increased.

The invention provides an application of DCTPP1 in detection of an auditing abortion kit, relates to the technical field of target spot diagnosis, and particularly provides an application of DCTPP1 as a target spot in preparation of an auditing abortion detection product, and an experimental result shows that DCTPP1 is one of key genes for auditing abortion. Specifically, after the DCTPP1 is knocked down from a human embryo trophoblast cell line HTR8 / SVneo, compared with a control group, the reduction of the DCTPP1 can cause more cell oxidation stress increase, and cell viability is reduced 24 hours later, and finally cell apoptosis occurs; in the mechanism, the DCTPP1 interacts with the RNA binding protein AUF1, and the reduction of the DCTPP1 causes the increase of oxidative stress of human embryo trophoblastic cells through the AUF1, so that apoptosis is caused. Experimental results in the application show that DCTPP1 is one of key genes for auditing abortion, and cell apoptosis can be finally caused by destroying the function of DCTPP1 in embryonic trophoblast cells through technologies such as transfection of specific siRNA and the like. In addition, the DCTPP1 knocked-down embryo trophoblast cells can be subjected to apoptosis, and the DCTPP1 knocked-down embryo trophoblast cells are one of useful genes for detecting and auditing abortion.

The present disclosure relates to antigen-binding molecules that bind to human and feline Human Trophoblast Cell Surface Antigen 2 (TROP2). The specific embodiments relate to antibody-drug conjugates (ADC) comprising saporin, mertansine and MMAE and chimeric antigen receptors (CAR) comprising said antigen-binding molecules for use in treatment of cancer.